Collplant Holdings (CLGN) AI Stock Analysis

• Market Cap: $28.74M
• Dividend Yield: N/A
• Average Volume (3M): 177.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.54
• Revenue Growth: 248.62%
• EPS Growth: 26.22%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 12,716,014
• 10 Day Avg. Volume: 34,638
• 30 Day Avg. Volume: 177,525
• PEG Ratio: -0.02
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 80.07
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 3.09
• Enterprise Value/Gross Profit: 5.92
• Enterprise Value/Ebitda: -0.60
• 1Y Price Target: $11.00
• Price Target Upside: 382.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: $2.50 ▲(9.65% Upside)

Collplant Holdings has a low overall stock score due to significant financial challenges, including declining revenue and negative cash flow. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. These factors collectively suggest a high-risk investment without clear positive catalysts.

Positive Factors

Innovative Product Development

The successful development of Collink.3D as a next-generation, animal-free extracellular matrix enhances CollPlant's position in tissue engineering, supporting long-term growth in regenerative medicine.

Strategic Partnerships

Collaboration with Mayo Clinic on a 3D bioprinted skin model underscores CollPlant's ability to form strategic partnerships, expanding its technological reach and market applications in regenerative medicine.

Market Expansion

Expanding the distribution network for VergenixSTR in Europe enhances CollPlant's market presence and potential revenue streams, supporting long-term growth in the regenerative medicine market.

Negative Factors

Revenue Decline

A significant revenue decline indicates challenges in product sales and market penetration, potentially impacting CollPlant's financial stability and ability to fund future growth initiatives.

Negative Cash Flow

Persistent negative cash flow reflects operational inefficiencies and may limit CollPlant's ability to invest in R&D and strategic initiatives, posing risks to long-term sustainability.

Weak Financial Stability

A declining equity ratio indicates weakening financial stability, which could constrain CollPlant's ability to secure financing and invest in growth opportunities, affecting long-term viability.

Collplant Holdings Business Overview & Revenue Model

Company Description

Collplant Holdings (CLGN) is a biotechnology company specializing in regenerative medicine and tissue repair. The company focuses on developing innovative solutions based on its proprietary collagen technology, which is derived from genetically modified tobacco plants. Collplant's core products include a range of collagen-based therapies and medical devices aimed at enhancing wound healing, tissue regeneration, and reconstructive surgery. The company operates primarily in the healthcare sector, targeting applications in orthopedics, aesthetic medicine, and other areas requiring tissue reconstruction and repair.

How the Company Makes Money

Collplant generates revenue through the commercialization of its collagen-based products and therapies. Its primary revenue streams include sales of medical devices and therapeutic products designed for wound care and tissue regeneration. Additionally, the company may engage in strategic partnerships with other healthcare firms, research institutions, and pharmaceutical companies to co-develop products or license its technology, further enhancing its revenue potential. Collaborations and partnerships may also provide funding through grants or milestone payments, contributing to its overall earnings. The company's focus on developing novel applications of its collagen technology positions it to capitalize on growing market demands in the regenerative medicine field.

Collplant Holdings Financial Statement Overview

Summary

Collplant Holdings is facing significant financial challenges, including a drastic revenue decline, negative profit margins, and deteriorating cash flow. Despite low debt levels, the company's shrinking assets and equity indicate financial instability, posing a substantial risk.

Income Statement

Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.

Cash Flow

Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.40M	515.00K	10.96M	299.00K	15.64M	6.14M
Gross Profit	1.25M	-1.11M	8.97M	-101.00K	13.64M	3.13M
EBITDA	-12.37M	-16.21M	-6.41M	-16.02M	838.00K	-4.94M
Net Income	-13.00M	-16.61M	-7.02M	-16.75M	409.00K	-5.81M
Balance Sheet
Total Assets	17.44M	18.71M	34.13M	37.77M	51.22M	10.84M
Cash, Cash Equivalents and Short-Term Investments	11.71M	11.91M	26.67M	29.65M	43.30M	3.33M
Total Debt	3.03M	3.08M	3.16M	2.91M	3.61M	3.39M
Total Liabilities	4.93M	5.25M	5.79M	5.49M	6.10M	6.36M
Stockholders Equity	12.51M	13.46M	28.34M	32.28M	45.12M	4.48M
Cash Flow
Free Cash Flow	-10.75M	-14.58M	-3.72M	-15.01M	912.00K	-4.97M
Operating Cash Flow	-10.54M	-14.09M	-2.76M	-13.70M	2.50M	-4.45M
Investing Cash Flow	-209.05K	-539.00K	-1.16M	28.92M	-31.56M	-519.00K
Financing Cash Flow	3.12M	9.00K	1.11M	1.87M	38.76M	4.46M

Collplant Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.28
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 2.28 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.53, and below the 200-day MA of 2.59, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 23.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.

Collplant Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$26.13M	―	-127.48%	―	-95.87%	35.25%
DARE	46 Neutral	$27.90M	-4.73	―	―	―	―
PASG	44 Neutral	$26.65M	―	-88.27%	―	―	32.57%
PYPD	41 Neutral	$32.41M	-0.90	-312.77%	―	―	61.18%
CLGN	40 Underperform	$28.74M	-2.02	-78.25%	―	248.62%	26.22%
NRSN	30 Underperform	$29.28M	―	―	―	―	31.09%

Collplant Holdings Corporate Events

CollPlant’s BioInk Outperforms Matrigel in Technion Study

On October 20, 2025, CollPlant Biotechnologies announced positive results from a study conducted by the Technion – Israel Institute of Technology, which demonstrated that its rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation. This suggests that Collink.3D™ could serve as a next-generation, animal-free extracellular matrix for advanced tissue engineering and research applications, potentially impacting the market for basement membrane matrices, which is projected to grow significantly by 2031.

CollPlant and Mayo Clinic Unveil Humanized 3D Bioprinted Skin Model

On October 16, 2025, CollPlant Biotechnologies announced the development of a first-of-its-kind fully humanized 3D bioprinted human skin model by Mayo Clinic researchers, utilizing CollPlant’s rhCollagen-based bioink. This model, which serves as an alternative to animal testing, has significant implications for cosmetic and pharmaceutical testing, disease modeling, and drug development, offering a sustainable and ethical solution while advancing regenerative medicine.

CollPlant Biotechnologies Reports Positive Non-Clinical Results for Regenerative Filler

On September 30, 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler. This product, which combines hyaluronic acid with a modified form of rhCollagen, is designed to offer both immediate and long-lasting benefits in aesthetic medicine. The successful completion of these studies marks a significant milestone for CollPlant as it prepares to advance the filler into clinical trials, potentially redefining standards in aesthetic treatments by integrating contouring precision, structural support, and tissue regeneration.

CollPlant Expands VergenixSTR Distribution in Europe

On September 15, 2025, CollPlant Biotechnologies announced the expansion of its European distribution network for its VergenixSTR product by signing a new agreement in Poland. VergenixSTR, a soft tissue repair matrix designed to treat tendinopathy, combines rhCollagen with platelet-rich plasma to promote tendon healing. This expansion is part of CollPlant’s strategy to broaden its global distribution network, enhancing its market presence in Europe and the Asia-Pacific region.

CollPlant Biotechnologies Transfers Listing to Nasdaq Capital Market

CollPlant Biotechnologies Ltd. announced that it has successfully transferred the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 12, 2025. This move is part of the company’s strategic efforts to optimize its market positioning while maintaining the trading symbol ‘CLGN’. The transfer is expected to have no impact on the trading of its shares, ensuring continuity for investors and stakeholders.

CollPlant Biotechnologies Advances Dermal Filler Program and Reports Q2 2025 Financial Results

On August 20, 2025, CollPlant Biotechnologies reported its financial results for the second quarter of 2025, highlighting significant advancements in its photocurable dermal filler program and regenerative breast implant technology. The company is preparing for clinical studies of its dermal filler, which has shown promising results in preclinical testing, and is expanding its market presence with new appointments and collaborations. CollPlant also reported a decrease in GAAP revenues for the quarter compared to the previous year, but an increase in revenues for the first half of the year due to a milestone payment from AbbVie. The company’s efforts to expand its product distribution and enhance its market position in the regenerative medicine industry are ongoing, with a focus on non-animal-derived collagen solutions.